The Quantellect read.As of Nov 19, 2026, 3 active firms cover Nautilus Biotechnology Inc: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $3.50 to $4.00, so the covering firms are broadly aligned. The average target of $3.83 sits 57% above the current $2.44. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.12 next quarter toward $-0.48 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$3.83
+56.8% upside
Average target across 3 active firms as of Nov 19, 2026 vs $2.45 current
Highest Target$4.00
Average Target$3.83
Lowest Target$3.50
Detailed analyst forecasts for NAUT
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate NAUT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
NAUT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.12
Range $-0.14 – $-0.09 · 3 analysts · +3% YoY
Next period, 3 analysts expect Nautilus Biotechnology Inc to earn $-0.12 a share (range $-0.14 – $-0.09), versus $-0.12 a year earlier. Full-year consensus is $-0.48, growing to $-0.48 the year after.
REVENUE · NEXT QUARTER
$387.5K
Range $200.0K – $500.0K · 3 analysts
Revenue is expected to reach $387.5K (range $200.0K – $500.0K). Full-year consensus is $668.5K, rising to $5.8M next year.
Top analysts covering Nautilus Biotechnology Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NAUT.
#1
Puneet Souda
Leerink Partners · Rank #30
Buy
$4.00+63.6% to target
Overall win rate
57%
+ Follow
#2
Matthew Sykes
Goldman Sachs · Rank #352
Sell
$1.75-28.4% to target
Overall win rate
38%
+ Follow
#3
Subbu Nambi
Guggenheim
Buy
$4.00+63.6% to target
Coverage
—
+ Follow
#4
Daniel Brennan
TD Cowen
Buy
No targeton NAUT
Coverage
—
+ Follow
NAUT stock forecast FAQ
What is NAUT's average 12-month price target?+
The 3 active firms with a live target average $3.83 for Nautilus Biotechnology Inc over the next 12 months, ranging from a $4.00 high to a $3.50 low, as of Nov 19, 2026.
Is NAUT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for NAUT?+
The Street-high target is $4.00 (Leerink Partners), and the Street-low is $3.50 (Roth Capital). The average of all 3 active-firm targets is $3.83.
How many active Wall Street firms cover NAUT?+
3 active firms have a recognized rating on Nautilus Biotechnology Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering NAUT?+
Among analysts who currently cover NAUT, Puneet Souda of Leerink Partners has the strongest overall Quantellect track record (Rank #30). Their current call is Buy with a $4.00 target.
What is Nautilus Biotechnology Inc's projected EPS for next quarter?+
The consensus estimate is $-0.12 per share (range $-0.14 – $-0.09) across 3 analysts. Full-year EPS is projected at $-0.48, rising to $-0.48 the following year.
How much revenue is Nautilus Biotechnology Inc expected to report next quarter?+
Consensus revenue is $387.5K (range $200.0K – $500.0K). Full-year revenue is projected at $668.5K, growing to $5.8M next year.
Have analysts been upgrading or downgrading NAUT lately?+
As of Nov 19, 2026, 3 of 3 active firms rate NAUT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NAUT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.